Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer
November 1st 2023The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
Read More
TTFields With SOC Shows Clinically Meaningful Overall Survival Improvement in Metastatic NSCLC
June 16th 2023The phase 3 LUNAR trial evaluating tumor treating fields (TTFields) with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer (NSCLC).
Read More